These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38313844)

  • 1. Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy.
    Liu C; Wu T; Ren N
    Front Endocrinol (Lausanne); 2023; 14():1268619. PubMed ID: 38313844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.
    Dhanapalaratnam R; Issar T; Lee ATK; Poynten AM; Milner KL; Kwai NCG; Krishnan AV
    Diabetologia; 2024 Mar; 67(3):561-566. PubMed ID: 38189936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.
    Mehta K; Behl T; Kumar A; Uddin MS; Zengin G; Arora S
    Curr Protein Pept Sci; 2021; 22(1):4-18. PubMed ID: 33292149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.
    Jaiswal M; Martin CL; Brown MB; Callaghan B; Albers JW; Feldman EL; Pop-Busui R
    J Diabetes Complications; 2015; 29(8):1287-94. PubMed ID: 26264399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.
    Jolivalt CG; Fineman M; Deacon CF; Carr RD; Calcutt NA
    Diabetes Obes Metab; 2011 Nov; 13(11):990-1000. PubMed ID: 21635674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.
    Fang H; Niu B; Chen Q
    Curr Med Chem; 2024; 31(20):2921-2943. PubMed ID: 37062063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic peripheral neuropathy essentials: a narrative review.
    Chang MC; Yang S
    Ann Palliat Med; 2023 Mar; 12(2):390-398. PubMed ID: 36786097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
    Himeno T; Kamiya H; Naruse K; Harada N; Ozaki N; Seino Y; Shibata T; Kondo M; Kato J; Okawa T; Fukami A; Hamada Y; Inagaki N; Seino Y; Drucker DJ; Oiso Y; Nakamura J
    Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy.
    Nagai Y; Mukai K; Otsuki M; Kimura T; Kozawa J; Nishizawa H; Maeda N; Matsuoka TA; Iwahashi H; Imagawa A; Shimomura I
    Intern Med; 2019 Apr; 58(7):949-953. PubMed ID: 30568127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.
    Rogliani P; Matera MG; Calzetta L; Hanania NA; Page C; Rossi I; Andreadi A; Galli A; Coppola A; Cazzola M; Lauro D
    Respir Med; 2019; 154():86-92. PubMed ID: 31228775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult.
    Mohiuddin MS; Himeno T; Inoue R; Miura-Yura E; Yamada Y; Nakai-Shimoda H; Asano S; Kato M; Motegi M; Kondo M; Seino Y; Tsunekawa S; Kato Y; Suzuki A; Naruse K; Kato K; Nakamura J; Kamiya H
    J Diabetes Res; 2019; 2019():9426014. PubMed ID: 30918901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
    Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
    Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnolol effectively ameliorates diabetic peripheral neuropathy in mice.
    Yang J; Wei Y; Zhao T; Li X; Zhao X; Ouyang X; Zhou L; Zhan X; Qian M; Wang J; Shen X
    Phytomedicine; 2022 Dec; 107():154434. PubMed ID: 36122436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.